心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光法)
Multiplex Assay Kit for Atrial Natriuretic Peptide (ANP) ,etc. by CBA (Cytometric Bead Array)
ANH; ANF; CDD; Atrial Natriuretic Factor; Atrial Natriuretic Hormone; Atriopeptin; Cardionatrine; Cardiodilatin
- 編號(hào)CMA225Eq
- 物種Equus caballus; Equine (Horse，馬)相同的名稱(chēng)，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍1.9531-2000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.651pg/mL.
- 樣本類(lèi)型Serum, plasma, tissue homogenates and other biological fluids
- 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格48T96T
- 價(jià)格¥ 3902¥ 5574
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 85-96 | 89 |
| EDTA plasma(n=5) | 84-97 | 90 |
| heparin plasma(n=5) | 95-103 | 99 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 96-105% | 79-94% | 78-101% | 86-102% |
| EDTA plasma(n=5) | 95-102% | 82-97% | 85-93% | 97-105% |
| heparin plasma(n=5) | 93-101% | 89-101% | 79-99% | 96-104% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1、向?qū)嶒?yàn)板每孔內(nèi)加入200μL分析緩沖液以預(yù)濕；
2、實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
3、加樣（標(biāo)準(zhǔn)品、樣本、磁珠），標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，25°C酶標(biāo)板振蕩器孵育2小時(shí)；
4、磁吸甩干，加檢測(cè)溶液A 100μL，25°C酶標(biāo)板振蕩器孵育1小時(shí)；
5、磁吸甩干，加檢測(cè)溶液B 100μL，25°C振動(dòng)孵育30分鐘；
6、磁吸洗板1次；
7、加鞘液100μL，旋渦震蕩10分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光法)抗體包被于磁性微球表面，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光法)抗體，加入PE標(biāo)記的親和素，用流式細(xì)胞儀讀數(shù)。MFI值和樣品中的心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光法)濃度呈正相關(guān)。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Equus caballus; Equine (Horse，馬) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA225Eq01 | 心鈉肽(ANP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| CPA225Eq21 | 心鈉肽(ANP)卵白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
| PAA225Eq01 | 心鈉肽(ANP)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA225Eq08 | 心鈉肽(ANP)多克隆抗體 | Testing in progress. |
| MAA225Eq21 | 心鈉肽(ANP)單克隆抗體 | WB; IHC; ICC; IP. |
| CEA225Eq | 心鈉肽(ANP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| CMA225Eq | 心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光法) | FLIA Kit for Antigen Detection. |
| LMA225Eq | 心鈉肽(ANP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| 8 | Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular Function[PubMed: 21616283] |
| Basic Research in Cardiology | Release of atrial natriuretic peptide precedes shedding of the endothelial glycocalyx equally in patients undergoing on- and off-pump coronary artery bypass surgery[PubMed: 21769675] |
| Neuropsychobiology. | Atrial natriuretic Peptide, arginine vasopressin Peptide and cortisol serum levels in opiate-dependent patients[PubMed: 23406607] |
| European addiction research | Alcohol-induced changes in methylation status of individual CpG sites, and serum levels of vasopressin and atrial natriuretic peptide in alcohol-dependent patients during detoxification treatment.[Pubmed: 24356727] |
| Crit Care. | Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx[Pubmed:25497357] |
| Diabet Med.? | Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes.[Pubmed:26927445] |
| J Ethnopharmacol | Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by reCavia (Guinea pig )lating p38 and NF-κb pathway[Pubmed:26970569] |
| Journal of Babylon University/Pure and Applied Sciences | Blood Pressure and Atrial Natriuretic Peptide (ANP) Levels in Patients with Autosomal Dominant Polycystic Kidney Disease.[papers:uobj_paper_2016_62613672.pdf] |
| PLoS One | Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy[pubmed:29240788] |
| Drug Delivery | Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy.[pubmed:29063791] |
| Elife | SIRT2 deacetylase regulates the activity of GSK3 isoforms independent of inhibitory phosphorylation[Pubmed:29504933] |
| Science?of the?Total?Environment | Co-exposure of silica nanoparticles and methylmercury induced cardiac toxicity and[Pubmed:29727991] |
| The Journal of Biological Chemistry | Toll-like receptor 2 deficiency hyperactivates the FoxO1 transcription factor and induces aging-associated cardiac dysfunction in mice[Pubmed:29929978] |
| Pediatric Cardiology | Determinants of Increased Aortic Diameters in Young Normotensive Patients With Turner Syndrome Without Structural Heart Disease[Pubmed:29392348] |
| FASEB?Journal | Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure[Pubmed: 30230922] |
| Endokrynologia Polska | Endothelin-1 (ET-1), N-terminal fragment of proatrial natriuretic peptide (NTpro-ANP) and tumor necrosis factor alpha (TNF-α) in children with primary hypertension?…[Pubmed: 30359461] |
| International Journal of Peptide Research and Therapeutics | ANP/NPRA Inhibits Epithelial-Mesenchymal Transition of Airway by Targeting Smad3 in Asthma[] |
| Van Veterinary Journal | Relationship between Natriuretic Peptide Levels with Heart and Kidney Parameters in Rats with Chronic Renal Failure.[] |
| Acta Pharmaceutica Sinica B | The poly (ADP-ribosyl) ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy[34094834] |
| Peptides | Alarin moderated myocardial hypertrophy via inhibiting cyclic adenosine monophosphate/protein kinase A signaling pathway to attenuate autophagy[34624429] |
| Peptides | Osteocrin alleviates cardiac hypertrophy via attenuating oxidative stress[Pubmed:35218795] |